Internal thoracic artery grafting confers a survival benefit even in the most elderly population undergoing coronary artery bypass grafting

即使是接受冠状动脉旁路移植术的最年长患者,内乳动脉移植也能带来生存获益。

阅读:1

Abstract

OBJECTIVE: Although the use of the left thoracic artery (LITA) is well accepted as the optimal conduit in coronary artery bypass graft surgery to improve survival, the survival benefit for the most elderly population is less well defined. Herein, we explore the lifetime benefit for use of the LITA versus saphenous vein grafting (SVG) only in a matched population of patients aged 80 years and older. METHODS: Retrospective review was conducted of consecutive patients aged 80 years and older who underwent isolated coronary artery bypass graft procedures using either SVG only or ITA + SVG grafting between June 1982 and December 2011. Propensity score matching, logistic regression, Kaplan-Meier survival analysis, and Cox regression were used to examine perioperative and long-term survival outcomes. RESULTS: There were 923 SVG patients and 1217 ITA + SVG patients. After propensity score matching there were 923 in each group. Follow-up ranged from 5 weeks to 25 years and was 99% complete. For matched patients, the operative mortality was 10.9% (101 out of 923) for SVG only and 7.8% (72 out of 923) (P = .021) for ITA + SVG. When examining long-term outcomes for hospital survivors, ITA + SVG was associated with improved survival (hazard ratio of mortality, 0.88; 95% CI, 0.80-0.97; P = .009). When stratifying the patients by age, it appeared that the survival benefit for ITA + SVG persisted well into the eighth decade of life but may be attenuated as patients approach age 90 years. CONCLUSIONS: Despite their advanced age and limited life expectancy, our data suggest that after adjusting for factors associated with selection bias, octogenarians enjoy long-term survival benefits from the use of ITA grafting.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。